NASDAQ:ARWR 25 November 2025

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals slipped roughly 0.7% to $64.10 Monday afternoon, following a session that saw the stock range from $61.48 up to $66.17.

9 February 2026

NASDAQ:ARWR·Pharmaceuticals·Stock Market

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE.

7 January 2026

Biotechnology·NASDAQ:ARWR·NASDAQ:WVE·Stock Market

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors.com

6 January 2026

Biotechnology·NASDAQ:ARWR·NYSE:LLY·Pharmaceuticals

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener

5 January 2026

Health News·NASDAQ:ARWR·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals Inc shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95.

30 December 2025

NASDAQ:ARWR·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals, Inc. is seeing a sharp pullback in Tuesday trading, with shares recently changing hands around $62—down roughly 9% from the prior close—after hitting an intraday low near $59.76.

16 December 2025

NASDAQ:ARWR·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals has quietly turned into one of 2025’s wildest biotech comeback stories. After years as a perpetually “promising” RNA interference platform, the company now has:

11 December 2025

Biotechnology·NASDAQ:ARWR·Pharmaceutical Industry

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. is ending 2025 in rare biotech air. The RNA interference specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2

9 December 2025

NASDAQ:ARWR·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2

8 December 2025

NASDAQ:ARWR·Pharmaceutical News

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks tied to its gene therapy Elevidys.

25 November 2025

Biotechnology·NASDAQ:ARWR·NASDAQ:SRPT·Pharmaceuticals·Stock Market

NASDAQ:ARWR 25 November 2025 - 9 February 2026